Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
Immune System Diseases
Namespace
mesh
Namespace Version
20180828
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh-names.belns

Appears in Networks 1

In-Edges 0

Out-Edges 3

path(MESH:"Immune System Diseases") increases path(MESH:Atherosclerosis) View Subject | View Object

At the same time, we have learnt that immune dysregulation contributes to prevalent diseases in Western societies such as atherosclerosis, type 2 diabetes, cancer and neurodegenerative diseases. PubMed:23702978

Annotations
Confidence
High

path(MESH:"Immune System Diseases") increases path(MESH:"Diabetes Mellitus, Type 2") View Subject | View Object

At the same time, we have learnt that immune dysregulation contributes to prevalent diseases in Western societies such as atherosclerosis, type 2 diabetes, cancer and neurodegenerative diseases. PubMed:23702978

Annotations
Confidence
High

path(MESH:"Immune System Diseases") increases path(MESH:"Neurodegenerative Diseases") View Subject | View Object

At the same time, we have learnt that immune dysregulation contributes to prevalent diseases in Western societies such as atherosclerosis, type 2 diabetes, cancer and neurodegenerative diseases. PubMed:23702978

Annotations
Confidence
High

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.